Neopterin in Acute Coronary Syndrome Patients

NCT ID: NCT05080387

Last Updated: 2022-02-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-11-01

Study Completion Date

2024-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Measurement of neopterin in ACS patients

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. Detect level of neopterin in ACS patients to detect whether there is relation or not between ACS and neopterin
2. Detection of relation between neopterin and cardiac enzymes as CK and troponine in ACS patients
3. Detect relation between neopterin level and in hospital events

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neopterin in Acute Coronary Syndrome Patients

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood sample

Blood samples will obtained for measurement of neopterin level through ELIZA

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patient of sample size admitted to cardiology departmentof Assiut university hospital with :

1. Acute typical chest pain
2. Positive cardiac enzymes
3. ECG show recent ischemic changes
4. ECHO show SWMA

2. Patients with other diseases which may cause increase of neopterin level as viral infections, intracellular bacteria or parasites infections, certain malignancies, allograft rejection
Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assiut University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mina Khairy Alyshaa Gorgy

Mina Khairy Alyshaa Gorgy

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Magdy Ibrahim Aldesowky, Lecturer

Role: PRINCIPAL_INVESTIGATOR

Assiut University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Assiut university

Asyut, , Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mina Khairy Alyshaa Gorgy, Resident

Role: CONTACT

01227386406

Yehia Taha keshik, Prof. Doctor

Role: CONTACT

01223971269

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Yehia Taha keshik, Prof . Doctor

Role: primary

01223971269

Magdy Ibrahim El desoky, Lecturer

Role: backup

01279950400

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Neopterin

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Protective Effect of Aspirin on COVID-19 Patients
NCT04365309 UNKNOWN PHASE2/PHASE3